Physician profile
Tourage Soleimani
NPI 1174573588
$8,239.67
in general payments reported to CMS, 2019-2025
32 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $1,041 · 2021: $1,924 · 2022: $1,312 · 2023: $928 · 2024: $905 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.18 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,398.24 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,259.28 | 2019-2025 | |
| Amgen INC. | $1,077.44 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $974.75 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $659.99 | 2019-2025 | Farxiga, Brilinta |
| Pfizer INC. | $549.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $503.77 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $283.67 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.67 | 2022-2025 | |
| Edwards Lifesciences Corporation | $185.66 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $164.09 | 2020-2023 | Verquvo |
| Abbott Laboratories | $140.86 | 2021-2025 | Jot Dx, Aveir, Gallant |
| Boston Scientific Corporation | $121.58 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $108.11 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $100.58 | 2019-2024 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $57.97 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $57.86 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $40.46 | 2019 | |
| Bridgebio Pharma, INC. | $28.28 | 2025 | Attruby |
| Irhythm Technologies, INC. | $26.59 | 2023 | Zio Xt Patch |
| Heartflow, INC. | $25.93 | 2025 | |
| Baxter Healthcare | $25.43 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Biotronik INC. | $24.85 | 2021 | |
| Medtronic, INC. | $22.99 | 2021 | |
| Esperion Therapeutics, INC. | $22.94 | 2021 | |
| Abbvie INC. | $22.31 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.48 | 2019 | |
| Preventice Services, LLC | $19.59 | 2021 | |
| Lilly USA, LLC | $18.07 | 2020 | |
| Allergan, INC. | $17.19 | 2019 | |
| Daiichi Sankyo INC. | $15.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tourage Soleimani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.